NCT01239394 2017-10-18
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Massachusetts General Hospital
Phase 2 Completed
Clinical Trials
3 trialsNCT01263418 2015-10-12
Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01119794 2015-08-26
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
Brown University
Phase 2 Terminated